All patients were diagnosed with high-risk adenocarcinoma of the prostate with a median pretreatment PSA of 11.5 ng/mL (IQR: 6.5 to 24.4 ng/mL). The gene discussed is KLK3; the disease is prostate adenocarcinoma.